These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22337948)

  • 1. HCV genotype-3a T cell immunity: specificity, function and impact of therapy.
    Humphreys IS; von Delft A; Brown A; Hibbert L; Collier JD; Foster GR; Rahman M; Christian A; Klenerman P; Barnes E
    Gut; 2012 Nov; 61(11):1589-99. PubMed ID: 22337948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.
    Cramp ME; Rossol S; Chokshi S; Carucci P; Williams R; Naoumov NV
    Gastroenterology; 2000 Feb; 118(2):346-55. PubMed ID: 10648463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection.
    Sreenarasimhaiah J; Jaramillo A; Crippin J; Lisker-Melman M; Chapman WC; Mohanakumar T
    Hum Immunol; 2003 May; 64(5):497-504. PubMed ID: 12691700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
    Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
    J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical responders to antiviral therapy of chronic HCV infection show elevated antiviral CD4+ and CD8+ T-cell responses.
    Pillai V; Lee WM; Thiele DL; Karandikar NJ
    J Viral Hepat; 2007 May; 14(5):318-29. PubMed ID: 17439521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy?
    Lee S; Hammond T; Watson MW; Flexman JP; Cheng W; Fernandez S; Price P
    Clin Exp Immunol; 2010 Jul; 161(1):118-26. PubMed ID: 20408862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design.
    von Delft A; Humphreys IS; Brown A; Pfafferott K; Lucas M; Klenerman P; Lauer GM; Cox AL; Gaudieri S; Barnes E
    Gut; 2016 Jan; 65(1):112-23. PubMed ID: 26092843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy.
    Kondo Y; Ueno Y; Ninomiya M; Tamai K; Tanaka Y; Inoue J; Kakazu E; Kobayashi K; Kimura O; Miura M; Yamamoto T; Kobayashi T; Igarashi T; Shimosegawa T
    J Gastroenterol; 2012 Dec; 47(12):1323-35. PubMed ID: 22588246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naturally occurring resistance mutations within the core and NS5B regions in hepatitis C genotypes, particularly genotype 5a, in South Africa.
    Prabdial-Sing N; Blackard JT; Puren AJ; Mahomed A; Abuelhassan W; Mahlangu J; Vermeulen M; Bowyer SM
    Antiviral Res; 2016 Mar; 127():90-8. PubMed ID: 26704023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.
    Aregay A; Owusu Sekyere S; Deterding K; Port K; Dietz J; Berkowski C; Sarrazin C; Manns MP; Cornberg M; Wedemeyer H
    J Hepatol; 2019 Nov; 71(5):889-899. PubMed ID: 31295532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfected with HCV and human immunodeficiency virus who responded to anti-HCV treatment.
    Legrand E; Neau D; Galperine T; Trimoulet P; Moreau JF; Pitard V; Lacut JY; Ragnaud JM; Dupon M; Le Bail B; Bernard N; Schvoerer E; Houghton M; Fleury H; Lafon ME
    J Infect Dis; 2002 Aug; 186(3):302-11. PubMed ID: 12134226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strain-specific T-cell suppression and protective immunity in patients with chronic hepatitis C virus infection.
    Sugimoto K; Kaplan DE; Ikeda F; Ding J; Schwartz J; Nunes FA; Alter HJ; Chang KM
    J Virol; 2005 Jun; 79(11):6976-83. PubMed ID: 15890937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of CD4
    Lucas M; Deshpande P; James I; Rauch A; Pfafferott K; Gaylard E; Merani S; Plauzolles A; Lucas A; McDonnell W; Kalams S; Pilkinton M; Chastain C; Barnett L; Prosser A; Mallal S; Fitzmaurice K; Drummer H; Ansari MA; Pedergnana V; Barnes E; John M; Kelleher D; Klenerman P; Gaudieri S
    Sci Rep; 2018 May; 8(1):7224. PubMed ID: 29740042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin.
    Amador-Cañizares Y; Martínez-Donato G; Alvarez-Lajonchere L; Vasallo C; Dausá M; Aguilar-Noriega D; Valenzuela C; Raíces I; Dubuisson J; Wychowski C; Cinza-Estévez Z; Castellanos M; Núñez M; Armas A; González Y; Revé I; Guerra I; Pérez Aguiar A; Dueñas-Carrera S
    World J Gastroenterol; 2014 Jan; 20(1):148-62. PubMed ID: 24415868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus.
    Rigopoulou EI; Abbott WG; Williams R; Naoumov NV
    Antiviral Res; 2007 Jul; 75(1):36-42. PubMed ID: 17210188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus-specific cellular immune responses in sustained virological responders with viral persistence in peripheral blood mononuclear cells.
    Roque-Cuéllar MC; Sánchez B; García-Lozano JR; Praena-Fernández JM; Márquez-Galán JL; Núñez-Roldán A; Aguilar-Reina J
    Liver Int; 2014 Jul; 34(6):e80-8. PubMed ID: 24127783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).
    Pilli M; Zerbini A; Penna A; Orlandini A; Lukasiewicz E; Pawlotsky JM; Zeuzem S; Schalm SW; von Wagner M; Germanidis G; Lurie Y; Esteban JI; Haagmans BL; Hezode C; Lagging M; Negro F; Homburger Y; Neumann AU; Ferrari C; Missale G;
    Gastroenterology; 2007 Oct; 133(4):1132-43. PubMed ID: 17919489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals.
    Burchill MA; Golden-Mason L; Wind-Rotolo M; Rosen HR
    J Viral Hepat; 2015 Dec; 22(12):983-91. PubMed ID: 26482547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response.
    Sugimoto K; Stadanlick J; Ikeda F; Brensinger C; Furth EE; Alter HJ; Chang KM
    Hepatology; 2003 Mar; 37(3):590-9. PubMed ID: 12601357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.
    Kamal SM; Fehr J; Roesler B; Peters T; Rasenack JW
    Gastroenterology; 2002 Oct; 123(4):1070-83. PubMed ID: 12360469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.